CHINA; UNITED STATES OF AMERICA —Pfizer Inc. has signed an exclusive worldwide collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, to develop and commercialize YP05002, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist currently in Phase 1 trials for chronic weight management.
Under the agreement, YaoPharma will complete the ongoing Phase 1 study, after which Pfizer will assume responsibility for further global development, manufacturing and commercialization. The transaction includes an upfront payment of USD 150 million, with additional milestone payments tied to development, regulatory and commercial achievements of up to USD 1.935 billion, along with tiered royalties on potential future sales.
Pfizer intends to evaluate YP05002 in combination regimens, including with its investigational glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, PF-07976016, currently in Phase 2 development, as well as other pipeline assets.
The agreement expands Pfizer’s footprint in the rapidly growing obesity therapeutics market, where GLP-1–based treatments have driven significant commercial activity. For investors and healthcare stakeholders, the deal underscores continued strategic investment in next-generation metabolic therapies and combination approaches targeting long-term weight management.
